tirzepatide clinical trial weight loss results Before and After: New Treatment Summary of clinical trials that
Description
While both medications belong to the GLP-1 family, Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, which means its mechanism of action is slightly different and may lead to different side effect profiles

The four-week intervals exist for safety, and shortening them increases side effect risk

*Available by prescription only, if medically appropriate
Ozempic: The similarities and differences There are a few key similarities and differences between Mounjaro and Ozempic

NexLife providers start patients on a lower dose and gradually titrate up to minimize side effects
Some patients lose 2 to 4 pounds from reduced appetite alone
